Join us on March 7 for our Educated Patient Summit on Breast Cancer taking place in Miami, FL! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Mantle Cell Lymphoma

Kristie L. Kahl And Neena Kennedy
Neena Kennedy, from the Leukemia and Lymphoma Society, offers advice on how to find out about and join clinical trials.
Dr. Simon Rule
Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.
Kristie L. Kahl
The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.
 
Kristie L. Kahl
Treatment with a CAR-T cell therapy showed promise in patients with mantle cell lymphoma, potentially leading to a new option for a group of individuals who have exhausted other options.
Jessica Skarzynski
However, the recent addition of new chemotherapy-free options such as chimeric antigen receptor (CAR)-T cell therapy could offer hope for patients with mantle cell lymphoma who develop resistance to chemotherapy-based treatment.
Jessica Skarzynski
While chemotherapy is widely used in the frontline treatment of mantle cell lymphoma (MCL), earlier use of BTK inhibitors such as Imbruvica (ibrutinib) may soon make chemotherapy obsolete for some patients, according to new data presented at the 2019 American Society of Hematology (ASH) Annual Meeting.
Katie Kosko
The Food and Drug Administration approved Brukinsa to treat relapsed and refractory mantle cell lymphoma, but what does this mean for patients?
Jessica Skarzynski
While resistance can often make it a challenge to treat mantle cell lymphoma, therapies have come a long way in recent years thanks to the emergence of personalized treatment and the use of BTK inhibitors, according to one expert.
Jessica Skarzynski
Researchers are expanding a clinical trial to include more patients with mantle cell lymphoma after some patients given the combination of medications under investigation showed no signs of cancer after treatment.
Beth Fand Incollingo
The Food and Drug Administration has approved Brukinsa to treat patients with mantle cell lymphoma whose disease has stopped responding to other medications or has recurred.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×